Patient & Clinical Data
Identifiers, diagnoses, treatments, observations, medication, notes and care history can create direct privacy and patient-impact concerns.
Healthcare & Life Sciences · Sensitive Data Controls
Control Sensitive Health & Research Data Without Blocking Approved Use
DataConsultant helps healthcare and life-sciences organisations identify where sensitive patient, clinical, research, genomic and AI data moves; define proportionate controls; assign accountability; and create implementation-ready evidence for safer, approved use across care, research, analytics and digital platforms.
✓Patient, clinical, trial, genomic and research-data context
✓Purpose, access, minimisation, sharing and lifecycle controls
✓Data-flow, lineage, evidence and accountable ownership
✓Implementation, assurance and operating-model support
Initial enquiries should describe the use case and environment. Do not send patient records, participant data, genomic files, credentials or other regulated production data through the contact form.
From Sensitive Data to Accountable Use
Illustrative control journey across healthcare and life sciencesPatient / ParticipantIdentity, purpose, consent and context
Care / ResearchEncounter, study, lab, imaging, trial
Clinical SystemsEHR, LIMS, PACS, EDC, CTMS, APIs
Analytics / AIData platforms, research, models, RAG
Approved SharingProviders, sponsors, partners, authorities
Data awareControls follow sensitivity and identifiability
Use awareControls reflect care, research, AI and sharing
Evidence awareOwners, exceptions and tests remain traceable
Sensitive-data centricPatient, participant, genomic, clinical and derived information
Care + research awareDifferent purposes, users, approvals, evidence and risk
Platform neutralWorks across clinical, research, cloud, analytics and AI estates
Risk and evidence ledPrioritise exposure pathways, owners, tests and remediation
Why the capability matters
Sensitive Healthcare Data Moves Through More Than the EHR
Care delivery, clinical research, digital health, analytics and AI can move the same person-linked information through systems, teams, vendors and secondary-use pipelines. The control problem is therefore not only “who can see the record”; it is whether approved purpose, identity, sensitivity, sharing, retention and evidence remain intact as data changes context.
Genomic & Biomarker Data
Highly identifying biological information can retain sensitivity even after obvious direct identifiers are removed.
Clinical Trial & Research Data
Study identity, consent, protocol, sponsor, site, subject coding, outcomes and external collaboration introduce distinct control boundaries.
Imaging, Lab & Device Data
DICOM metadata, laboratory results, device telemetry and associated identifiers can persist across diagnostic and data-platform workflows.
Safety & Pharmacovigilance
Adverse-event and safety records can combine patient, reporter, product, event and regulator-relevant information.
External & Third-Party Sharing
Labs, CROs, sponsors, processors, cloud providers, partners and research collaborators expand trust boundaries and exit obligations.
Analytics & AI Reuse
Feature engineering, RAG, prompt logs, derived attributes, model outputs and secondary datasets can create new inference or disclosure paths.
Retention & Evidence
Copies, exports, backups, study archives, audit trails and downstream replicas can outlive the original business purpose if ownership is unclear.
Transformation view
From Fragmented Sensitive-Data Handling to a Traceable Control State
The target is not a single privacy tool. It is an operating capability that connects data sensitivity and approved use to technical enforcement, evidence, exception handling and accountable decisions.
Current state — higher exposure, weaker evidence
- Patient and research data inventories are incomplete or manually maintained
- Access reflects application roles rather than purpose and data sensitivity
- Pseudonymisation, masking and exports are inconsistent across pipelines
- Consent, ethics approvals or intended use are not connected to downstream processing
- Third-party copies and retention obligations are difficult to trace
- AI prompts, retrieval sources, logs or outputs introduce unmanaged sensitive-data paths
- Control exceptions and residual risks lack clear owners and evidence
Target state — proportionate controls, accountable use
- Critical sensitive-data domains, stores and flows are identified and classified
- Purpose, role, least privilege and segregation requirements drive access decisions
- De-identification, pseudonymisation, encryption and export patterns are standardised
- Consent, approved-use and research-governance dependencies are explicit
- Sharing, retention, deletion and exit controls are traceable across third parties
- AI and analytics use is governed from source data through model output and monitoring
- Control ownership, evidence, testing, exceptions and remediation are measurable
Healthcare & life-sciences process context
Controls Follow the Care-to-Research Value Chain
A useful control design maps where sensitive information is produced, enriched, combined, consumed and shared—not just where it is stored.
Registration & Identity
Patient or participant identity, demographics, consent and eligibility
Care Encounter
Clinical notes, diagnosis, medication, observations and care plans
Diagnostics
Laboratory, imaging, pathology, device and test-result data
Treatment & Outcomes
Interventions, response, follow-up, safety and longitudinal history
Research & Trials
Study enrolment, protocol, eCRF, samples, endpoints and sponsor data
Genomics & Biomarkers
Sequence, variant, molecular, phenotype and specimen relationships
Analytics & AI
Cohorts, features, model inputs, retrieval, outputs and human review
Exchange & Reporting
Providers, partners, sponsors, authorities, publications and downstream users
Data-domain view
Sensitive Controls Must Understand Relationships Between Health Data Domains
Identifiability and risk can change when previously separate data is linked. The control model therefore considers direct identifiers, quasi-identifiers, clinical content, research codes, biological data and derived outputs together.
Patient / Participant IdentityIdentifiers, demographics, contact, account, study subject codeIdentity anchor
Consent / PurposeCare, research, sharing, preference, withdrawal, approved useUse boundary
Encounter & ClinicalDiagnosis, procedure, medication, notes, observations, outcomesClinical context
Laboratory & ImagingResults, pathology, DICOM, specimen, device and test metadataDiagnostic context
Provider & FacilityClinician, organisation, site, specialty, care team, locationAccountability
Trial & ResearchProtocol, site, cohort, eCRF, endpoint, randomisation, study dataResearch context
Genomic & BiomarkerSequence, variants, molecular assays, phenotype, biobank linkageHigh identifiability
Safety / PharmacovigilanceAdverse event, reporter, product, seriousness, causality, follow-upSafety context
Billing / Payer / OperationsCoverage, claims, invoices, service codes, operational identifiersCommercial context
Analytics / AI OutputsFeatures, cohorts, embeddings, prompts, inferences, scores, generated textDerived sensitivity
Control implication: “De-identified”, “coded”, “pseudonymised” and “anonymous” are not interchangeable labels. The appropriate terminology and control strength should be validated against the actual transformation, re-identification path, approved purpose and applicable legal or regulatory definition.
Service scope
What the Sensitive Data Controls Service Covers
The engagement connects sensitive-data inventory and approved use to enforceable controls, evidence and an operating model. Each workstream is tailored to the organisation’s care, research, technology and regulatory environment.
Discover & InventoryStores, flows, copies, exports, third parties
Classify & ContextualiseSensitivity, identifiability, purpose, use
Define AccessRole, purpose, segregation, approval, privilege
Minimise & TransformMasking, tokenisation, pseudonymisation
Control SharingAPIs, downloads, partner transfer, export
Manage LifecycleRetention, archival, deletion, holds, backups
Monitor & EvidenceLogs, alerts, tests, exceptions, decisions
Remediate & OperateBacklog, owners, forums, reporting, review
Control taxonomy
A Healthcare Sensitive-Data Control Model Built Around Actual Use
Controls should be layered. A system can be encrypted and still expose sensitive data through excessive access, inappropriate purpose, unmanaged exports, weak pseudonymisation, permissive AI prompts or uncontrolled downstream sharing.
Identity, consent & purposeWho the person is, why data is used, approvals and withdrawal dependencies
Classification & handlingSensitivity, identifiability, criticality, labels and approved handling patterns
Access & segregationLeast privilege, break-glass, study/site separation, privileged access and review
Transformation controlsMasking, redaction, tokenisation, pseudonymisation and re-identification governance
Encryption & key dependenciesData at rest/in transit, secrets, key custody, rotation and platform responsibilities
Sensitive
Health Datapurpose · context · evidence
Health Datapurpose · context · evidence
Export, DLP & sharingDownloads, APIs, messaging, removable media, email and third-party exchange
Retention & deletionTrigger, archive, legal/quality holds, downstream deletion, backup dependencies
Audit, lineage & evidenceAccess logs, data lineage, approvals, control tests, exceptions and remediation
Third-party & transfer controlsProcessors, CROs, labs, cloud, sub-processors, residency, onward sharing and exit
Research & AI use controlsCohorts, training, RAG, prompts, outputs, inference, human review and change gates
Use case → control mapping
Different Healthcare Uses Need Different Sensitive-Data Tests
The same dataset can require different controls when used for direct care, research, external collaboration, product development or AI. The table below is illustrative; final requirements depend on approved purpose and applicable obligations.
| Business / research use | Potential sensitive-data concern | Primary control questions | Evidence to capture | Decision outcome |
|---|---|---|---|---|
| Direct patient careEHR and clinical workflow | Excessive access, break-glass misuse, cross-facility visibility | Role, treatment relationship, privileged access, emergency override, logging | Role map, access rules, override logs, review records | Approved use with monitored access |
| Research cohortingSecondary data use | Purpose expansion, re-identification, weak cohort isolation | Approved purpose, minimisation, pseudonymisation, researcher access, output checking | Study approval, transformation logic, access and export evidence | Controlled research workspace |
| Clinical trial operationsEDC / CTMS / eTMF | Subject-code linkage, site/sponsor segregation, external collaboration | Role segregation, code key custody, protocol use, transfer, archival | Data flow, role matrix, code-key control, transfer records | Study-specific control baseline |
| Genomic analyticsSequence and phenotype | High identifiability, familial inference, long-lived sensitivity | Necessity, isolation, re-identification path, external sharing, output disclosure | Purpose map, transformation, environment controls, sharing register | Enhanced control review |
| PharmacovigilanceSafety-case processing | Patient/reporter data, mandatory reporting, vendor handoffs | Minimum required fields, role access, secure exchange, retention and auditability | Case flow, transfer controls, access, retention and evidence map | Purpose-linked safety controls |
| Clinical AI / decision supportModel or GenAI workflow | Sensitive prompts, retrieval leakage, inferred health data, unsafe outputs | Allowed data, retrieval permissions, logging, output handling, human oversight, vendor use | Model/data flow, test set, access map, monitoring and decision log | Assurance + human-review gate |
| External data sharingPartner / sponsor / authority | Over-sharing, wrong recipient, onward transfer, retention after purpose | Recipient, purpose, fields, transfer, encryption, onward use, exit and deletion | Sharing approval, interface control, recipient obligations, deletion evidence | Approved transfer with traceability |
Technical architecture
Where Sensitive-Data Controls Sit in a Healthcare Technology Estate
The exact stack varies by organisation. The architecture below shows control placement rather than assuming particular products or vendors.
EHR / EMREncounters, diagnoses, notes, medication, orders
LIMS / PathologySpecimens, tests, results and laboratory workflow
PACS / ImagingImages, DICOM metadata and diagnostic reporting
EDC / CTMS / eTMFClinical trials, study operations and regulated records
Genomics / BiobankSequence, variant, biomarker and sample relationships
Apps / APIs / FHIRDigital health, interoperability, partners and exchange
Identity & access · purpose / consent signals · classification · masking / tokenisation · encryption · API / export controls · DLP · secrets · logging · retention · incident evidence
Integration & InteroperabilityInterfaces, messaging, API gateways, transformations, data contracts
Data PlatformWarehouse, lakehouse, research enclave, curated clinical data
Analytics & BIDashboards, cohort analysis, quality, operations and research insight
AI / ML / GenAIFeatures, training, RAG, prompts, outputs, monitoring and human review
Governance & evidence plane: ownership · metadata · lineage · data quality · privacy / legal input · security · research ethics · quality / compliance · AI assurance · exceptions · control testing · management reporting
Operating model
Sensitive Data Control Is a Cross-Functional Decision System
Technical enforcement is only sustainable when accountability is explicit across care, research, privacy, security, data, quality and AI teams.
Risk-based prioritisation
Prioritise Controls by Sensitivity, Exposure and Consequence
This illustrative matrix is a decision aid, not a client risk rating. Final severity criteria should align with the organisation’s approved risk methodology and specialist input.
Factor
Lower
Moderate
High
Critical
Identifiability
Aggregated / strongly de-identified
Pseudonymised with separation
Direct or linkable identifiers
Identity + highly sensitive content
Data sensitivity
Low sensitivity context
General personal / operational
Clinical / research sensitive
Genomic / highly consequential
Exposure path
Restricted internal
Broader approved workforce
External / export / cloud path
Public or uncontrolled disclosure
Use consequence
Low-impact analysis
Operational decision support
Care / research / eligibility impact
Material patient or participant harm
Control evidence
Tested + monitored
Implemented, limited evidence
Manual / inconsistent
Absent or ineffective
Regulatory & standards context
Control Design Must Be Grounded in the Organisation’s Actual Obligations
Healthcare and life sciences can span privacy law, digital-health policy, clinical-research ethics, information security, regulated electronic records and contractual requirements. The references below are examples of current authoritative sources that may inform an engagement where applicable.
India DPDP Act, 2023 & Rules, 2025
INDIA · AS APPLICABLEIndia’s digital personal-data framework may shape purpose, notice, security safeguards, breach, retention and accountability requirements depending on the processing context and commencement timeline.
India Code: DPDP Act ↗MeitY: DPDP Rules 2025 ↗
ABDM Health Data Management Policy
INDIA DIGITAL HEALTHThe policy is a security- and privacy-by-design guidance point for the ABDM ecosystem, including federated health-data exchange, consent and protection expectations.
NHA / ABDM policy PDF ↗EHR Standards for India 2016
INDIA HEALTH ITMoHFW’s EHR standards provide an official reference point for electronic health-record interoperability, information structure and related health-information practices.
MoHFW standard PDF ↗ICMR Ethical Guidelines
INDIA RESEARCHBiomedical and health research involving human participants may require ethics, consent, confidentiality, data and governance considerations aligned with current institutional and ICMR expectations.
ICMR guidelines ↗ISO 27799:2025
HEALTH SECURITYISO 27799:2025 provides health-sector information-security controls and implementation guidance based on ISO/IEC 27002:2022 for health organisations and custodians of health information.
ISO 27799:2025 ↗HIPAA Security Rule
US · WHERE APPLICABLEFor HIPAA regulated entities, the current Security Rule requires administrative, physical and technical safeguards for electronic protected health information (ePHI).
HHS Security Rule summary ↗EU GDPR Article 9
EU / EEA · WHERE APPLICABLEGDPR treats health data, genetic data and certain biometric data as special categories of personal data and establishes conditions and safeguards for permitted processing.
EUR-Lex GDPR ↗FDA Electronic Records Guidance
US LIFE SCIENCES · WHERE APPLICABLEFDA guidance addresses electronic systems, electronic records and signatures used in clinical investigations, including trustworthiness, reliability and regulated-record expectations.
FDA final guidance ↗Client Policies & Contracts
ALWAYS CONTEXTUALInternal privacy, security, research, quality, records, AI and vendor policies plus data-sharing and sponsor contracts can create requirements beyond public frameworks.
Map your control obligations →Important: Applicability depends on jurisdiction, entity type, business model, care or research activity, products, systems, data handled, contracts and authorised legal or regulatory interpretation. DataConsultant supports readiness and implementable control design; it does not provide a guarantee of compliance, statutory audit, legal opinion, regulatory approval or certification.
Delivery methodology
How DataConsultant Delivers a Sensitive Data Controls Engagement
The work progresses from decision and data-flow understanding to control design, evidence, prioritisation and mobilisation. The sequence can be narrowed for a focused assessment or expanded into implementation and ongoing operations.
1. Align Scope & DecisionsUse cases, domains, systems, stakeholders, jurisdictions, outcomes
2. Discover Sensitive DataInventory stores, interfaces, extracts, replicas, logs and third parties
3. Map Purpose & FlowWho uses what data, for which approved purpose, through which path
4. Assess Risk & ControlsExposure, identifiability, access, sharing, retention, AI and evidence gaps
5. Design Target ControlsRequirements, patterns, ownership, exceptions, acceptance criteria
6. Validate & PrioritiseEvidence review, severity rationale, dependencies and remediation order
7. Mobilise ImplementationBacklog, owners, architecture decisions, tests, rollout and training
8. Operate & ImproveMonitoring, issues, changes, reassessment, reporting and transfer
Tangible outputs
Deliverables Built for Decisions, Implementation and Assurance
The final pack is selected according to the question the organisation must answer—assessment, design approval, implementation, remediation, audit support, research use, AI release or operating-model mobilisation.
Sensitive Data Inventory
Prioritised data categories, domains, systems, locations, copies, owners, third parties and known handling context.
DISCOVERYData Flow & Trust-Boundary Maps
Source-to-use movement across applications, interfaces, data platforms, research environments, partners and AI paths.
TRACEABILITYClassification & Handling Model
Sensitivity tiers, identifiers, approved handling patterns, labelling expectations and escalation criteria.
STANDARDControl Requirements Catalogue
Purpose, access, segregation, transformation, sharing, encryption, retention, monitoring and evidence requirements.
CONTROL DESIGNAccess & Segregation Model
Role, purpose, break-glass, privilege, study/site boundaries, approval, review and revocation requirements.
IAMPseudonymisation / Tokenisation Design
Transformation patterns, code-key or vault separation, re-identification governance, output controls and limitations.
PRIVACY ENGINEERINGRetention & Deletion Matrix
Triggers, archive, holds, backup dependencies, downstream copies, third-party obligations and evidence of disposal.
LIFECYCLEAI & Research Use Requirements
Approved datasets, secondary use, RAG, prompts, model/vendor use, output handling, human review and change gates.
AI / RESEARCHThird-Party Sharing Controls
Recipient, purpose, minimum fields, interfaces, transfer safeguards, onward use, incident, retention and exit requirements.
ECOSYSTEMControl Test & Evidence Plan
What should be tested, evidence expected, owner, frequency or trigger, pass criteria and exception process.
ASSURANCEPrioritised Remediation Backlog
Finding, risk rationale, affected process/data, owner, dependency, proposed treatment and acceptance criteria.
ACTIONOperating Model & Decision Pack
Roles, forums, decision rights, metrics, escalation, implementation roadmap and executive decisions required.
OPERATEEvaluation & remediation roadmap
A Phased Route From Discovery to Sustainable Control
Implementation can start with one high-risk domain or use case and expand as patterns are validated. Phase gates, dependencies and evidence should be agreed before broad rollout.
1
Align & Scope
Decisions, data, stakeholders, obligations and boundaries
2
Inventory & Map
Sensitive data, systems, flows, sharing and copies
3
Assess Controls
Access, purpose, transformation, lifecycle and evidence
4
Design Target
Patterns, standards, architecture and operating model
5
Pilot Priority Flow
Implement and validate one bounded control pattern
6
Scale & Integrate
Roll out tooling, workflows, monitoring and training
7
Reassess & Improve
Test changes, close gaps, monitor and update controls
What we need from the client
Evidence and Decision-Maker Access Are More Important Than Perfect Documentation
Missing evidence is recorded as a limitation rather than assumed. A focused engagement can begin with partial inventories if accountable stakeholders can validate what is known and prioritise gaps.
Business & Research Context
Priority use cases, care or study workflows, approved purposes, data consumers, decisions and known constraints.
Useful inputs: process maps, protocols, use-case briefsData & System Landscape
Application and data-platform inventories, data categories, interfaces, APIs, extracts, reporting and AI environments.
Useful inputs: architecture, flow and integration diagramsPrivacy & Regulatory Inputs
Approved internal interpretations, notices, consent models, ethics decisions, contractual restrictions and records obligations.
Useful inputs: policies, DPIAs, study approvals, agreementsSecurity & Access Evidence
Roles, privileged access, authentication, encryption dependencies, logging, DLP, incidents and third-party access.
Useful inputs: IAM matrices, control standards, audit evidenceOperational Findings
Known privacy, security, quality, audit, research, platform or AI issues and current remediation activity.
Useful inputs: findings, tickets, exception and risk registersAccountable Stakeholders
Clinical, research, data, privacy, security, quality, legal, platform and AI owners who can validate evidence and make decisions.
Useful inputs: RACI, governance forums, escalation routesImplementation & ongoing support
Support Can Continue From Control Design Into Operation
Implementation and managed support are scoped separately. DataConsultant can work with internal teams and existing vendors while keeping client decision rights, legal interpretation, system ownership and risk acceptance explicit.
01
Design
Requirements, patterns, policies, architecture, ownership and acceptance criteria.
02
Mobilise
Prioritised backlog, programme governance, roles, tool requirements and pilot scope.
03
Implement
Control configuration advisory, data-flow changes, classification, IAM, metadata and testing support.
04
Operate
Governance forums, exceptions, control monitoring, evidence reporting and issue coordination.
05
Improve / Transfer
Reassessment, change gates, metrics, training, runbooks and transfer to internal ownership or CoE.
Commercial clarity
Custom Scope & Pricing
No fixed DataConsultant fee or duration is published for this industry service. The commercial model should reflect the actual healthcare or life-sciences environment, evidence requirements and implementation depth.
What affects effort, timeline and price
A bounded assessment of one sensitive-data flow is materially different from an enterprise programme spanning facilities, studies, geographies, platforms and ongoing operations.
Care / research use casesData domains & sensitivityFacilities, studies & sitesJurisdictionsSystems & integrationsThird parties / CROs / labsAI models & data pathsControl testing depthEvidence availabilityStakeholder groupsImplementation scopeManaged support / training
Buyer guidance
When This Service Is the Right Starting Point
Use Sensitive Data Controls when the core problem is how sensitive healthcare or life-sciences data is accessed, transformed, shared, retained or reused. A different starting service may be better when the primary issue is legal opinion, penetration testing, general data quality or a broad enterprise strategy.
Good fit
- Patient, clinical, research or genomic data moves across multiple systems or organisations.
- Access, exports, pseudonymisation, retention or sharing controls are inconsistent.
- A new data platform, research environment, interoperability programme or AI use case needs sensitive-data design.
- Audit, privacy, security, ethics or quality findings require a cross-functional remediation plan.
- Leadership needs traceable ownership, evidence and prioritised control improvements.
May require another or additional service
- A formal legal opinion, regulatory representation or statutory certification is the primary requirement.
- The need is penetration testing, incident forensics or specialist cyber-response work.
- The problem is only data accuracy or completeness with no material sensitive-data control dimension.
- A broad data/AI strategy or architecture programme must first establish enterprise direction.
- No accountable sponsor or access to relevant system/data owners is available.
Why DataConsultant
Connect Sensitive-Data Risk to Data Architecture and Operating Change
The service is designed as enterprise data consulting—not a software resale, checklist exercise or generic privacy template.
Healthcare data context
Controls are mapped to patient, clinical, trial, research, genomic, safety and approved AI/data use rather than generic “PII” labels.
Architecture + governance together
Data flows, IAM, privacy, security, metadata, lineage, quality and operating roles are treated as one implementation system.
Evidence-conscious assurance
Findings distinguish confirmed evidence, assumptions, gaps, dependencies, residual risk and matters needing authorised specialist review.
Implementation and transfer
Support can continue into mobilisation, control rollout, monitoring, governance operations, training and capability transfer when scoped.
Related capabilities
Adjacent Data, Privacy, Security and AI Services
Sensitive data controls often sit inside a broader programme. These verified DataConsultant capabilities can be combined when the requirement extends beyond the control scope on this page.
Frequently asked questions
Healthcare & Life Sciences Sensitive Data Controls FAQs
Direct answers to common buyer questions about scope, applicability, implementation, technology, AI, regulatory context, timing and commercial treatment.
What are sensitive data controls in healthcare and life sciences?
Sensitive data controls are the business, governance, technical and operational measures used to limit how patient, clinical, research-subject, genomic, laboratory, imaging and other sensitive information is collected, accessed, combined, shared, retained, analysed and used. Effective controls connect approved purpose and data classification to identity, access, minimisation, pseudonymisation, encryption, transfer, retention, monitoring, evidence and accountable ownership.
What is included in DataConsultant’s Healthcare and Life Sciences Sensitive Data Controls service?
Scope can include sensitive-data discovery and classification, data-flow and trust-boundary mapping, purpose and consent dependencies, access and segregation requirements, masking or pseudonymisation design, encryption and key-governance dependencies, export and sharing controls, retention and deletion requirements, third-party controls, monitoring, evidence, AI and research-use controls, target operating model, remediation backlog and implementation support. Final scope is confirmed during discovery.
Which healthcare and life-sciences data domains can be assessed?
Depending on the organisation, the assessment can cover patient and member identity, encounters, diagnoses, observations, laboratory results, imaging, medications, clinician and facility data, research participants, clinical-trial data, genomic and biomarker data, biobank data, safety or pharmacovigilance data, medical-device data, payer or billing data and approved analytics or AI datasets. Only domains relevant to the agreed business and regulatory context are included.
Does the service replace legal, privacy, cybersecurity or regulatory advice?
No. DataConsultant can structure facts, data flows, control requirements, evidence and implementation options, but formal legal interpretation, statutory audit, certification, penetration testing, clinical-safety judgement and regulatory approval remain with appropriately authorised specialists and accountable client functions.
How are India’s DPDP framework and ABDM considerations handled?
Where relevant, the engagement can map approved interpretations of India’s Digital Personal Data Protection Act and Rules, together with applicable ABDM policies or interoperability requirements, into practical data requirements and controls. Applicability depends on the organisation, processing purpose, system participation, data flow and current legal or regulatory interpretation; the service does not assume that every requirement applies to every organisation.
Can HIPAA, GDPR or FDA-regulated electronic-record requirements be considered?
Yes, where those regimes are relevant to the organisation and agreed scope. For example, controls may be mapped to approved requirements for ePHI under HIPAA, special-category health or genetic data under GDPR, or electronic records used in FDA-regulated activities. Jurisdiction-specific conclusions must be validated by authorised legal, privacy, quality or regulatory specialists.
How does the service address clinical research and genomic data?
The work can separate participant identity from research datasets, map consent and approved-use dependencies, define role and study segregation, control exports and external collaboration, specify pseudonymisation or coding patterns, record lineage and provenance, govern re-identification pathways, define retention or archival requirements and strengthen evidence for ethics, privacy, quality and sponsor oversight.
How are AI and generative-AI use cases handled?
AI use is assessed through the real data path: source data, retrieval or grounding, model input, prompt, memory, output, logs, human review, downstream action and vendor interfaces. Controls can cover prohibited sensitive-data use, minimisation, de-identification, access, prompt and output handling, model or vendor data-use terms, testing, human oversight, monitoring and change review. No AI accuracy, safety or compliance outcome is guaranteed.
Can DataConsultant work with our existing EHR, LIMS, PACS, CTMS, EDC, cloud and analytics platforms?
Yes. The service is requirements-led and can assess the organisation’s existing applications, interfaces, APIs, data platforms, identity systems, privacy tooling, security controls, analytics and AI environments. DataConsultant does not assume a specific vendor stack; platform-specific configuration is included only when explicitly scoped.
What deliverables can we expect?
Typical outputs can include a sensitive-data inventory, classification and handling model, data-flow and trust-boundary maps, control requirements catalogue, access and segregation model, pseudonymisation or tokenisation design, consent and purpose dependencies, retention and deletion matrix, third-party sharing controls, AI or research-use requirements, evidence and testing plan, prioritised findings, implementation backlog, operating model and executive decision pack.
How long does a sensitive data controls engagement take?
Timeline is confirmed after scoping. It depends on the number of data domains, systems, sites or studies, jurisdictions, stakeholder groups, evidence availability, control depth, technical validation, review cycles, implementation requirements and whether the work covers one priority use case or an enterprise programme.
How is pricing determined?
DataConsultant does not publish a fixed fee for this healthcare and life-sciences service. Pricing is scope-led and depends on data domains, systems, facilities or studies, jurisdictions, stakeholder groups, assessment depth, data-flow complexity, control testing, required deliverables, workshops, implementation support, onsite needs and ongoing operating support. A written scope and estimate can be prepared after initial discovery.
Can DataConsultant help implement and operate the controls after the assessment?
Yes. Implementation support can be scoped separately for control requirements, backlog mobilisation, data classification, access governance, metadata and lineage, data-quality controls, pseudonymisation patterns, privacy workflows, monitoring, governance forums, evidence reporting, AI assurance, training and managed data-governance operations. Client accountability, legal decisions, system ownership and risk acceptance remain clearly assigned.
Sensitive Data Controls Enquiry
Request a Scope Review
Share your contact details and a non-sensitive description of the requirement. DataConsultant can review the likely scope, evidence needs, stakeholder involvement and appropriate next step.